| Bioactivity | Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research[1][2][3]. |
| Invitro | Cofetuzumab pelidotin (PF-06647020) 对表达 PTK7 的癌细胞系 H446、H661 和 OVCAR3 具有体外细胞毒性作用，EC50 值分别为 7.6、27.5 和 105 ng/mL[1]。Cofetuzumab pelidotin (持续 6 天)在一组癌细胞系 (A549、MDA-MB-468、KYSE-150、SKOV-3、PC9、NCI-H1975) 细胞中显示出高效力和 PTK7 特异性细胞毒性，IC50 为 0-1100 nM[2]。Cofetuzumab pelidotin 稳定性较差，T1/2 不足 3 天[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Cofetuzumab pelidotin 相关抗体: |
| In Vivo | Cofetuzumab pelidotin (PF-06647020；3 mg/kg；腹腔注射，每周两次，持续四个周期) 对 NSCLC、OVCA 和 TNBC 的 PDX 小鼠模型产生显着抗肿瘤作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1869937-48-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Marc Damelin, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017 Jan 11;9(372):eaag2611. [2]. Chao Kong, et al. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Mol Cancer Ther. 2023 Oct 2;22(10):1128-1143. [3]. Masaru Katoh. Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis. nn Transl Med. 2017 Dec;5(23):462. |